PRESS RELEASE
News
-
-
REGULATED PRESS RELEASE
TINC publiceert voortreffelijke resultaten voor het verlengde boekjaar 2022-2023 (18 maanden)
TINC publiceert voortreffelijke resultaten voor het verlengde boekjaar 2022-2023 met een nettowinst van € 50,9 miljoen en bruto uitkering aan aandeelhouders van € 0,84 per aandeel. Sterkste investeringsjaar ooit met € 171,5 miljoen nieuwe investeringen -
REGULATED PRESS RELEASE
TINC publishes outstanding results for extended financial year 2022-2023 (18 months)
TINC publie des résultats exceptionnels pour l'exercice financier prolongé 2022-2023 (18 mois). Les bénéfices augmentent avec un rendement annuel de 9,88% et une distribution de 0,84€ par action -
REGULATED PRESS RELEASE
TINC publishes outstanding results for extended financial year 2022-2023 (18 months)
TINC reports outstanding results for extended financial year 2022-2023 with a net profit of €50.9 million and a proposed gross distribution of €0.84 per share. Strongest investment year ever with €171.5 million in new commitments -
PRESS RELEASE
AI/ML Innovations Inc.’s Health Gauge Launches "Follow Your Heart": A Revolutionary Non-Invasive Blood Pressure Measurement Solution
Health Gauge Inc. announces the commercial launch of 'Follow Your Heart,' a smartwatch with medical-grade accuracy for blood pressure monitoring. The product caters to individuals managing hypertension and aims to provide reliable and accessible monitoring solutions -
PRESS RELEASE
IFF Management Analysts Offer Market Report Insight on Australia's Inflation Trends
Australia's consumer price inflation remains steady at a two-year low of 3.4% in January, indicating RBA's likely continuity in monetary policy. IFF Management analysts decode the latest data from the Australian Bureau of Statistics -
PRESS RELEASE
South Star Battery Metals Announces Closing of Tranche 2 of Oversubscribed, Non-Brokered Private Placement and Two-Year Extension of the BamaStar Landowners/Mineral Rights Agreement
South Star Battery Metals Corp. announces successful closing of oversubscribed non-brokered private placement, raising additional gross proceeds for exploration and development activities -
PRESS RELEASE
NX Development Corp. is Granted Orphan-Drug Designation Status by US FDA for Gleolan(R) in Ovarian and Related Cancers
NX Development Corp. has achieved orphan-drug status from the FDA for Gleolan, aiding in the visualization of ovarian tumors during surgery. The milestone highlights innovation in cancer care and surgery -
-
